Review

1. Cancer drug resistance:rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
2. Circulating non-coding RNAs in recurrent and metastatic ovarian cancer
3. Computational analyses for cancer biology based on exhaustive experimental backgrounds
4. Dodging the bullet:therapeutic resistance mechanisms in pediatric cancers
5. Drug-adapted cancer cell lines as preclinical models of acquired resistance
6. Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets
7. Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein
8. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies
9. lnnate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers
10. lnsights into breast cancer phenotying through molecular omics approaches and therapy response
11. lnvolvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
12. Long non-coding RNAs regulation of therapeutic resistance
13. Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy
14. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors
15. Mechanisms of resistance to anti-angiogenic treatments
16. Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
17. MicroRNAs and cancer drug resistance:over two thousand characters in search of a role
18. Mitochondrial determinants of chemoresistance
19. Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies
20. PARP inhibitors:clinical development,emerging differences,and the current therapeutic issues
21. Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
22. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators
23. Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
24. Role of circulating tumor cell spheroids in drug resistance
25. Stress and drug resistance in cancer
26. Tailored therapy in patients treated with fluoropyrimidines:focus on the role of dihydropyrimidine dehydrogenase
27. Targeting MYCN and ALK in resistant and relapsing neuroblastoma
28. Targeting the “undruggable” RAS - new strategies - new hope?
29. The effects of growth hormone on therapy resistance in cancer
30. The role of exosomal microRNAs; focus on clinical applications in breast cancer
31. Use of MRl,metabolomic,and genomic biomarkers to identify mechanisms of chemoresistance in glioma

Original Article

1. Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
2. MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
3. Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells:the quest for microRNAs' involvement in cancer drug resistance

Case Report

1. Longitudinal monitoring for the emergence of epidermal growth factor C797S resistance mutations in non-small cell lung cancer using blood-based droplet digital PCR

Perspective

1. Enhanced Kat3A/Catenin transcription:a common mechanism of therapeutic resistance